Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
51.25
-1.25 (-2.38%)
Jan 21, 2026, 4:08 PM HKT
-29.21%
Market Cap10.44B
Revenue (ttm)n/a
Net Income (ttm)-314.72M
Shares Out198.89M
EPS (ttm)-2.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume242,100
Average Volume453,987
Open52.50
Previous Close52.50
Day's Range51.25 - 54.00
52-Week Range44.72 - 83.60
Betan/a
RSI46.65
Earnings DateNov 28, 2025

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 192
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.